Weight loss & GLP-1 Peptides
18 compounds in this group, 5 of them with an FDA-approved product. Grouping follows what each compound is studied or marketed for; it does not mean the use is proven.
All weight loss & glp-1 compounds (A–Z)
| Compound | FDA status | PubMed papers | Last 5 years | Registered trials | Class |
|---|---|---|---|---|---|
| 5-Amino-1MQ | Not approved (research only) | 3 | 3 | 0 | NNMT inhibitor (small molecule) |
| Adipotide | Not approved (research only) | 3 | 0 | 0 | Peptidomimetic targeting fat vasculature |
| AICAR | Not approved (research only) | 2,433 | 523 | 0 | AMPK activator (nucleoside) |
| AOD-9604 | Not approved (research only) | 22 | 4 | 0 | Modified GH fragment 177-191 |
| Cagrilintide | Investigational | 103 | 103 | 44 | Long-acting amylin analog |
| Cagrilintide + semaglutide | Investigational | 27 | 27 | 0 | Amylin + GLP-1 combination |
| HGH fragment 176-191 | Not approved (research only) | 1 | 1 | 0 | Growth hormone fragment |
| L-carnitine | FDA-approved | 300 | 131 | 313 | Amino acid derivative |
| Liraglutide | FDA-approved | 5,683 | 2,893 | 515 | GLP-1 receptor agonist |
| Mazdutide | Investigational | 54 | 54 | 43 | GLP-1 / glucagon dual agonist |
| MOTS-c | Not approved (research only) | 259 | 207 | 5 | Mitochondrial-derived peptide |
| O-304 | Investigational | — | — | 0 | AMPK activator (small molecule) |
| Retatrutide | Investigational | 202 | 202 | 33 | GIP / GLP-1 / glucagon triple agonist |
| Semaglutide | FDA-approved | 5,707 | 5,279 | 788 | GLP-1 receptor agonist |
| Survodutide | Investigational | 87 | 87 | 29 | GLP-1 / glucagon dual agonist |
| Tesamorelin | FDA-approved | 95 | 34 | 24 | GHRH analog |
| Tesofensine | Investigational | 52 | 5 | 13 | Monoamine reuptake inhibitor |
| Tirzepatide | FDA-approved | 2,637 | 2,630 | 303 | GIP / GLP-1 dual agonist |
Frequently asked questions
Which weight loss & glp-1 peptides are FDA-approved?
5 of the 18 have an FDA-approved product: L-carnitine, Liraglutide, Semaglutide, Tesamorelin and Tirzepatide. Research-grade vials sold online are not those approved products.
Which weight loss & glp-1 peptides have the most research?
By PubMed records: Semaglutide (5,707), Liraglutide (5,683) and Tirzepatide (2,637). 5 have fewer than 25 indexed papers, mostly cell or animal work.
Which have registered human trials?
11 appear on ClinicalTrials.gov, led by Semaglutide (788), Liraglutide (515), L-carnitine (313) and Tirzepatide (303). Cagrilintide, Cagrilintide + semaglutide, Mazdutide, O-304, Retatrutide, Survodutide and Tesofensine are still investigational.
Comparisons
Semaglutide vs TirzepatideTirzepatide vs RetatrutideSemaglutide vs LiraglutideTirzepatide vs Liraglutide
Reconstitution math
Semaglutide 20 mg vial mathSurvodutide 10 mg vial mathMazdutide 10 mg vial mathRetatrutide 30 mg vial mathAICAR 50 mg vial mathL-carnitine 200 mg vial mathMOTS-c 5 mg vial math5-Amino-1MQ 50 mg vial mathCagrilintide 10 mg vial mathTesamorelin 10 mg vial mathTesamorelin 20 mg vial mathAOD-9604 10 mg vial math
Other categories
Growth hormone & GHRHTissue repair & recoveryAnti-aging & longevityCognitive, neuro & sleepBlends & stacksSexual & reproductive healthImmune supportBioregulators & other research compounds
Protocol hub: Weight loss & GLP-1 protocols and vial math.
Evidence ranking: best weight loss peptides.